KMPH - ケムファ―ム (KemPharm Inc.) ケムファ―ム

 KMPHのチャート


 KMPHの企業情報

symbol KMPH
会社名 KemPharm Inc (ケムファ―ム)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 ケムファーム(KemPharm Inc.)は、新規分子実体(NME)プロドラッグの発見・開発に従事する米国の臨床段階特殊医薬品会社である。同社は、自社リガンド活性化療法(LAT)プラットフォーム技術を通じて、NMEプロドラッグ製品候補の作成を行う。そのNMEプロドラッグ製品候補は疼痛治療用KP201/APAP、KP511/ERとKP606/ER、注意欠陥多動性障害(ADHD)治療用KP415、及び中枢神経系(CNS)障害治療用KP303を含む。KP201/APAPは臨床試験段階にあり、KP511/ER、KP415、KP606/ER及びKP303は前臨床試験段階にある。   ケムファ―ムは、米国の製薬会社。リガンド活性化療法を採用し、処方・承認薬を向上させる独自のプロドラッグの発見と開発に従事。おもな製品候補として、急性および中程度から重度の疼痛の治療薬であるKP201/APAP(ヒドロコドンとアセトアミノフェンから構成される)の開発を手掛ける。   KemPharm is a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs to treat serious medical conditions through its proprietary LAT™ (Ligand Activated Therapy) technology. KemPharm utilizes its proprietary LAT™ technology to generate improved prodrug versions of FDA-approved drugs as well as to generate prodrug versions of existing compounds that may have applications for new disease indications. KemPharm's prodrug product candidate pipeline is focused on the high need areas of attention deficit hyperactivity disorder, or ADHD, and stimulant use disorder. KemPharm's co-lead clinical development candidates for the treatment of ADHD, KP415 and KP484, are both based on a prodrug of d-methylphenidate, but have differing duration/effect profiles. In addition, KemPharm has received FDA approval for APADAZ®, an immediate-release combination product containing benzhydrocodone, a prodrug of hydrocodone, and acetaminophen.
本社所在地 2500 Crosspark Road Suite E126 Coralville IA 52241 USA
代表者氏名 Travis C. Mickle トラビス・ミクル
代表者役職名 Chairman of the Board President Chief Executive Officer 取締役会長兼最高経営責任者(CEO)
電話番号 +1 319-665-2575
設立年月日 38991
市場名 NASDAQ National Market System
ipoyear 2015年
従業員数
url www.kempharm.com
nasdaq_url https://www.nasdaq.com/symbol/kmph
adr_tso
EBITDA EBITDA(百万ドル) -46.10100
終値(lastsale) 2.61
時価総額(marketcap) 41869666.98
時価総額 時価総額(百万ドル) 60.83858
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 123.47358
当期純利益 当期純利益(百万ドル) -56.75900
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 KemPharm Inc revenues was not reported. Net loss increased 59% to $36.2M. Higher net loss reflects Fair value adjustment related to derivat increase of 13% to $4.2M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$1.56 to -$2.42.

 KMPHのテクニカル分析


 KMPHのニュース

   Is KemPharm Inc (KMPH) A Good Stock To Buy?  2021/06/29 13:01:16 Insider Monkey
   KemPharm - Redesigning Approved Drugs For Better Efficacy And Safety  2021/06/28 00:29:09 Seeking Alpha
   KemPharm Shares Drop 12% After Warrant Exchange - Morningstar  2021/06/24 06:56:25 Morningstar
KemPharm Shares Drop 12% After Warrant Exchange Morningstar.com
   Why KemPharm Stock Sank Today  2021/06/18 20:01:17 The Motley Fool
Investors reacted negatively to the company''s warrant exchange.
   KemPharm exercises existing warrants and issues new ones in private placement  2021/06/18 13:34:26 Seeking Alpha
   Why KemPharm Stock Sank Today  2021/06/18 20:01:17 The Motley Fool
Investors reacted negatively to the company''s warrant exchange.
   KemPharm exercises existing warrants and issues new ones in private placement  2021/06/18 13:34:26 Seeking Alpha
   KemPharm Announces Exercise of Existing Warrants and Issuance of Warrants in Private Placement  2021/06/18 13:15:00 Intrado Digital Media
CELEBRATION, Fla., June 18, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced it has entered into agreements with certain of its holders of its existing warrants exercisable for 6,117,509 shares of its common stock, in the aggregate, pursuant to which such holders agreed to exercise their warrants for cash in exchange for the Companys agreement to issue in a private placement new warrants to purchase up to 1,529,379 shares of its common stock. The new warrants are immediately exercisable and have substantially the same terms as the existing warrants, except that the new warrants have an exercise price of $16.50 per share and expire on December 31, 2026. The aggregate gross proceeds from the exercise of the existing warrants and the issuance of the new warrants are expected to total approximately $39.1 million, before deducting the financial advisory fees.
   KemPharm Issues Letter to Shareholders  2021/06/16 11:30:00 Intrado Digital Media
CELEBRATION, Fla., June 16, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that Travis C. Mickle, Ph.D., President and CEO of KemPharm, has issued a Letter to Shareholders in connection with the Companys 2021 Annual Meeting of Stockholders to be held on June 17, 2021. The letter provides an update on recent events and outlook for the remainder of 2021 and early 2022.
   Why This News Could Help KemPharm Stock Break Out: A Technical Analysis  2021/06/10 18:51:47 Business Insider Markets
KemPharm Inc. (NASDAQ: KMPH ) shares moved higher Thursday after it was announced the company is being added to the Russell 3000
   The Daily Biotech Pulse: KemPharm Receives $10M Milestone Payment, Zymergen, Neuropace Debut On Nasdaq, Renalytix Wins US Government Contract, 2 IPOs  2021/04/22 08:08:00 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 21) …
   KemPharm Amends Licensing Agreement With Gurnet Point Capital, Increases Milestone Payments To $590M  2021/04/09 11:00:02 Benzinga
KemPharm Inc (NASDAQ: KMPH ) has amended the collaboration and license agreement with Gurnet Point Capital (GPC), a private investment firm. The agreement provides for an exclusive worldwide license to develop, manufacture, and commercialize KemPharm's product candidates containing serdexmethylphenidate (SDX) and d-methylphenidate (d-MPH). The deal also includes Azstarys (formerly referred to as KP415) for … Full story available on Benzinga.com
   KemPharm Announces Amendment to Licensing Agreement with Gurnet Point Capital Affiliate Following FDA Approval of AZSTARYS(TM)  2021/04/08 20:05:44 MarketWatch
CELEBRATION, Apr 08, 2021 (GLOBE NEWSWIRE via COMTEX) -- Amendment Increases Total Potential Regulatory and Sales Milestone Payments to $590 Million, and…
   Attention Biotech Investors: Mark Your Calendar For April PDUFA Dates  2021/04/02 12:00:21 Benzinga
A slew of drugs, including four new molecular entities, were approved in the month of March. NMEs are drugs that contain active moieties that have never been approved by the Food and Drug Administration previously and are indicators of innovation in drug research. Among the notable approvals that came through in the month were Abecma, the first-ever cell therapy for a type of blood cancer; Fotivda, AVEO Pharmaceuticals, Inc.'s (NASDAQ: AVEO ) oral, next-generation therapy for treating advanced renal cell carcinoma; and KemPharm, Inc.'s (NASDAQ: KMPH ) Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder in patients age six years and older. PDUFA dates are binary events that invariably serve as make-or-break catalysts for stocks. These dates are deadlines by which the FDA reviews a new drug application before announcing its decision concerning the approvability/non-approvability of the drug. Here are the key FDA approvals scheduled for April. Acadia Hopes Against Hope to Get Label Expansion Psychosis Drug Company: ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) Type of Application: supplemental new drug application Candidate: pimavanserin Indication: dementia Date: April 3 Pimavanserin, which is marketed under the trade name Nuplazid, has already been approved by the FDA for the treatment of hallucinations associated with Parkinson's disease psychosis.
   KMPH Stock: Why Twitter Thinks KemPharm Is the New GME Short Squeeze  2021/03/16 15:02:10 InvestorPlace
KemPharm (KMPH) stock is gaining interest on Twitter (TWTR) from retail traders that think it might be the next GameStop (GME).

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 ケムファ―ム KMPH KemPharm Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)